EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis

Shanshan Jin, Zhengqiang Hu, Yuancheng Jin, Wang Lv, Zhujin Song, Su Zeng, Miaolian Wu

Frontiers in Public Health · 2026

DOI: 10.3389/fpubh.2026.1763592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Shanshan Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine,…. Hauptthemen laut MEDLINE: Hydrazines, Benzoates, Pyrazoles, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Thrombopoietin receptor agonists (TPO-RAs) are standard second-line therapies for chronic immune thrombocytopenia (ITP). Given the introduction of domestic options like hetrombopag, a comparative economic evaluation is essential to inform reimbursement policies in China. This study assessed the cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for Chinese adults with chronic ITP.

Methods

A hybrid model comprising a decision tree and a Markov process was developed to simulate lifetime costs and health outcomes from the perspective of the Chinese healthcare system. Clinical efficacy parameters were derived from randomized controlled trials and a network meta-analysis (NMA). Utilities and costs were estimated using published literature and local data, respectively. Future costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. The primary outcome was the incremental net monetary benefit (iNMB) at a willingness-to-pay (WTP) threshold of CNY 287,391/QALY. Deterministic and probabilistic sensitivity analyses were performed to evaluate uncertainty.

Results

Over a lifetime horizon, hetrombopag was the lowest-cost strategy (CNY 2,205,717), followed by eltrombopag (CNY 2,214,322) and avatrombopag (CNY 2,379,335). Although avatrombopag yielded the highest QALYs (10.449), hetrombopag (10.335 QALYs) dominated eltrombopag (10.159 QALYs) by providing greater health benefits at lower costs. Compared with avatrombopag, hetrombopag generated a positive iNMB of CNY 140,864, as the substantial cost savings outweighed the marginal reduction in QALYs. Probabilistic sensitivity analysis indicated that hetrombopag had the highest probability of being cost-effective across standard WTP thresholds.

Conclusion

Under current pricing, hetrombopag represents the most cost-effective second-line TPO-RA for adult chronic ITP in China. It dominates eltrombopag and offers a favorable economic profile compared with avatrombopag. These findings support the use of hetrombopag as a preferred option in resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrazinesBenzoatesPyrazolesPurpura, Thrombocytopenic, IdiopathicThiazolesTriazolesHumansCost-Benefit AnalysisCost-Effectiveness AnalysisChinaQuality-Adjusted Life YearsChronic DiseaseAdultFemaleMarkov ChainsMaleMiddle AgedHydrazonesThiophenesPyrazolones

Stichwörter der Autor:innen

avatrombopagchronic immune thrombocytopeniacost-utility analysiseltrombopaghetrombopagthrombopoietin receptor agonists

Substanzen

HydrazinesBenzoateseltrombopagPyrazolesavatrombopaghetrombopagThiazolesTriazolesHydrazonesThiophenes

Autor:innen und Institutionen

  • Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
  • Research Center for Clinical Pharmacy, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Pharmacy, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.

Zitieren

APA

Jin, S., Hu, Z., Jin, Y., Lv, W., Song, Z., Zeng, S., & Wu, M. (2026). Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1763592

Vancouver

Jin S, Hu Z, Jin Y, Lv W, Song Z, Zeng S, et al. Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1763592

BibTeX
@article{Jin2026,
  author = {Jin, Shanshan and Hu, Zhengqiang and Jin, Yuancheng and Lv, Wang and Song, Zhujin and Zeng, Su and Wu, Miaolian},
  title = {Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis},
  journal = {Frontiers in Public Health},
  year = {2026},
  doi = {10.3389/fpubh.2026.1763592}
}
Kostenlos starten →